Today: 18 July 2026
Browse Category

Biotechnology 26 September 2025 - 15 October 2025

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion (NASDAQ:EVAX) Stock Rockets After AI-Powered Cancer Vaccine Breakthrough

Evaxion’s stock jump in mid-October comes as the company lines up important clinical updates and validates its AI-driven vaccine technology. On Oct 13, Evaxion announced it will present two-year data from its Phase 2 trial of EVX-01 at the ESMO Congress in Berlin globenewswire.com. The October presentation will cover efficacy, immunogenicity, safety, best overall response, and T‑cell response durability of EVX-01 plus Merck’s KEYTRUDA® globenewswire.com. Earlier one-year interim results showed a 69% overall response rate and tumor reduction in 15 of 16 patients globenewswire.com, highlighting the vaccine’s promise. Evaxion’s CSO/Interim CEO Birgitte Rønø emphasized that being selected for an ESMO oral presentation “is a testament to the interest in EVX-01 and the field of personalized cancer vaccines” globenewswire.com.
15 October 2025
···
Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

Arcadia Biosciences Stock Rockets Amid Trade News – What’s Behind RKDA’s Wild Ride?

In-Depth: Arcadia’s stock price has been extremely volatile in October 2025, jumping ~68% pre-market on Oct 15. The rally was sparked by a Trump tweet on China trade and follows mixed Q2 results. In the past few days RKDA’s trading range has widened dramatically. After closing at $3.69 on Oct 14 stockanalysis.com, pre-market Oct 15 it was near $6.22 stockanalysis.com, on very high volume. This wild move came as commodity and agri-tech stocks rallied on geopolitical news.
15 October 2025
···
Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough

Genprex shares have been extremely volatile. After surging over 30% during regular hours on Oct 14, 2025, to about $0.25, the stock jumped another 41% in after-hours trading to roughly $0.36 on the cancer data announcement benzinga.com benzinga.com. That rally brought the stock briefly near its 30-day resistance around $0.26 ainvest.com. Before this spike, GNPX had been trading around $0.20. Over the last five trading days the stock was up about 25.6%, although year‐to‐date it was still down roughly 70% benzinga.com. For context, GNPX’s 52-week high is ~$4.09 and its 52-week low is about $0.22 google.com benzinga.com.
15 October 2025
···
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside

Intellia was an early pioneer of in-vivo CRISPR therapy. Based in Cambridge, MA, it was among the first to administer CRISPR-Cas9 therapies directly into patients ts2.tech. In 2021 Intellia reported the first clinical proof that in-body CRISPR editing could work – a single injection dramatically lowered the disease protein in ATTR amyloidosis patients ts2.tech. Today, the company’s focus is on curative gene edits in severe diseases. Its lead programs are NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema ts2.tech ts2.tech. Both use CRISPR delivered via lipid nanoparticles to knock out genes with one dose. Intellia’s partnerships have fueled its pipeline: a 2016 deal with Regeneron co-developed NTLA-2001 ts2.tech, and Regeneron later expanded the alliance to other targets. Other collaborations include AvenCell, Kyverna, ONK Therapeutics and ReCode, which use Intellia’s platform to engineer cell therapies or improve delivery ts2.tech. These alliances help the small company leverage resources while concentrating on its late-stage in-vivo programs. Recent restructuring and discontinuation of a Phase 1 program reflect Intellia’s narrow focus on ATTR and HAE ts2.tech.
9 October 2025
··
AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

AI Drug Discovery Goldmine? Inside Recursion Pharma’s Wild Stock Surge and What’s Next

After languishing through the summer, Recursion’s share price came to life in early October 2025. By Oct 8 the stock had rebounded to around $6.09 insidermonkey.com, putting it near the middle of its volatile 52-week range ts2.tech. For context, RXRX had traded in the double-digits when AI hype in biotech peaked earlier in the year, then slid into the high-$3s during industry sell-offs ts2.tech. Even after this week’s pop, shares remain ~30% lower than a year ago ts2.tech. Such dramatic swings are not unusual for a pre-revenue biotech stock – especially one at the intersection of two hot themes that can amplify volatility.
9 October 2025
···
Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real?

Xenetic’s stock was relatively quiet for most of 2025 until early October, when it suddenly erupted. By Oct 8, 2025, XBIO had skyrocketed to levels not seen in years. On that day alone, the stock soared 123% to $9.58finanzen.ch, after touching intraday highs well above $10. This move extended a remarkable run from under $3.50 at the start of the week to nearly $12-13 intraday on Oct 8ainvest.com. In fact, at one point XBIO was up about +195% in a single session according to real-time trackerstimothysykes.com. Such gains are extraordinary – even by penny stock standards – and placed XBIO among the top percentage gainers across the entire Nasdaq.
8 October 2025
··
Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna, Inc. (MRNA) Stock Update – Oct 8 2025: Will the mRNA Trailblazer Bounce Back or Sink Further?

Moderna’s stock was a market darling during the pandemic but has suffered a long decline. On Oct 7 2025, the stock closed at $27.34, down roughly 0.7% from $27.54 on the prior sessionstockinvest.us. Technical analysts at Stockinvest.us noted the shares were near the upper part of a wide falling trend and predicted a possible trading range of $26.40–$28.73 on Oct 8, with longer‑term support around $26 and resistance near $31stockinvest.us. While short‑term signals were positive, they cautioned that the overall downward trend remainsstockinvest.us.
8 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects

Intellia’s October rally was triggered by longer‑term Phase 1 results for nexiguran ziclumeran, an in‑vivo CRISPR therapy for transthyretin amyloidosis. A GlobeNewswire release reported that a single dose produced a rapid, deep and durable reduction of serum TTR levels—mean reduction 92 % at 24 months and 90 % at 36 monthsglobenewswire.com. Patients also showed clinical improvements or stabilization of neuropathy and cardiac markersglobenewswire.com, and safety findings were mostly mild infusion‑related eventsglobenewswire.com. CEO John Leonard said the data “demonstrate rapid, deep and durable TTR reductions with meaningful clinical improvements” and reiterated plans to complete enrolment in the Phase 3 MAGNITUDE‑2 trial in the first half of 2026globenewswire.comglobenewswire.com.
8 October 2025
··
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside

According to AAII, CRSP’s share price on 8 Oct 2025 closed at $77.727, up 10.06 % from the previous close. The stock traded between $70.77 and $78.38 that day and has risen ~20 % during October. Over the prior year the share price ranged from $30.04 to $73.95, and year‑to‑date performance stood at +97.5 %. Trading volume on INDmoney’s quote was 3.1 million sharesindmoney.com.
8 October 2025
·
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company at the forefront of CRISPRgene editing medicines. Headquartered in Cambridge, MA, Intellia was one of the first companies to harness CRISPR-Cas9 technology to develop potential in vivo therapies – treatments delivered directly into the body to edit genes inside patients’ cells. In fact, Intellia reported the first-ever clinical evidence that CRISPR could provide a therapeutic benefit in humans via in-body gene editing, showing in 2021 that a one-time IV infusion could drastically lower a disease-causing protein in patients ts2.tech. This pioneering achievement, accomplished with their transthyretin amyloidosis program, has put Intellia on the map as a trailblazer in genomic medicine.
8 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharmaceuticals, Inc. is redefining drug discovery by combining cutting-edge biology and data science. Based in Salt Lake City, this “TechBio” pioneer uses automation, massive datasets and machine learning to identify new therapies faster than traditional labsdirectorstalkinterviews.comnasdaq.com. Its mission – “to decode biology to radically improve lives” – has attracted major industry partners and bold investors. But as an early-stage biotech with no approved drugs, Recursion’s stock can be a rollercoaster ride, swayed by scientific milestones and market sentiment alike.
8 October 2025
···
No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

No-Revenue Biotech Soars 64,000% – Is Regencell (RGC) a Breakthrough or a Bubble?

Regencell Bioscience is an early-stage biotech company focused on Traditional Chinese Medicine. Headquartered in Causeway Bay, Hong Kong, Regencell researches, develops, and aims to commercialize herbal treatment formulae for neurocognitive disorders – primarily Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder Marketbeat Insidermonkey. The company’s approach is based on the “Sik-Kee Au TCM Brain Theory,” a proprietary herbal methodology developed by the CEO’s father ts2.tech.
7 October 2025
··
Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough – Inside the Stock Surge, Pipeline & Outlook (Oct 2025)

Spruce Biosciences’ stock chart for 2025 looks like a hockey stick – mostly flat/down all year and then vertical in October. On Monday, Oct 6, SPRB opened around $8.60 and skyrocketed to $130.40 by the close after the FDA news. The 52-week high was shattered in the process. Volume surged into the tens of millions of shares, far exceeding the tiny float, as investors clamored for a piece of the action. The rally continued after hours, and in pre-market trading Tuesday shares jumped almost another 90% at one point.
7 October 2025
··
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Pharmaceuticals is a biopharma focused on eye care. Its flagship product XDEMVY was FDA-approved in July 2023 as the first-ever treatment for Demodex blepharitis globenewswire.com. Tarsus reports that XDEMVY’s launch has exceeded expectations – CEO Bobak Azamian called the Q2 results their “strongest quarter to date” and emphasized XDEMVY as the new standard of care nasdaq.com. Management notes more than 20,000 eye doctors are now prescribing XDEMVY nasdaq.com, backed by national TV advertising globenewswire.com and an expanded sales team. The company now covers >90% of U.S. patients nasdaq.com, and patient engagement has surged with the marketing push nasdaq.com.
3 October 2025
···
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (CDTX) Stock Soars After $339M BARDA Flu-Drug Deal – Is CD388 the Next Big Flu-Fighter?

On Friday morning Oct 3, CDTX was trading around $104 per share, up roughly 5.7% from Thursday’s close finviz.com. Trading volumes are high as investors digest the Oct 2 BARDA award news. Cidara’s one-year chart is steeply upward – from around $10 a year ago to over $100 now. Most of that gain occurred since June, after positive Phase 2b results for CD388 and the $402M financing.
3 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

Analysis: GRAIL’s stock performance reflects a wave of optimism about its Galleri cancer-screening test and pending trial results. In late September it broke out to new highs, aided by momentum and positive chatter. The company itself is pushing the narrative: GRAIL President Dr. Josh Ofman proclaims Galleri’s data will usher in a “transformative era for cancer screening,” detecting cancers earlier “when they can be easier to treat and are potentially curable” grail.com.
3 October 2025
···
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained

SRPT has been a roller-coaster. In early 2025, Sarepta’s shares were largely pummeled by the DMD gene-therapy crisis. After two Duchenne patients died in June and FDA urged a full pause, the stock plunged to decade lows Nasdaq Biospace. On July 17, Sarepta partially paused Elevidys for all patients, and FDA did as well – shares briefly hit the low teens.
3 October 2025
··
Nebius (NBIS) Stock Rockets on $17B Microsoft AI Deal – Explosive Growth & Outlook Revealed

Biotech Boom: NBIS Surges After Microsoft‑NeoCloud AI Deal – Is a New Bull Market Ahead?

The Nasdaq Biotechnology Index tracks companies listed on the Nasdaq Stock Market that are classified as biotechnology or pharmaceutical businesses. The index is modified‑capitalisation weighted, meaning larger companies carry more influence but weightings are capped to enhance diversification. It started with a base value of 200 in 1993 and currently contains around 251 components indexes.nasdaqomx.com. The index is widely followed because it provides a benchmark for biotech investors and is the basis for several exchange‑traded funds.
2 October 2025
····
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia–OpenAI Partnership: Nvidia announced a landmark collaboration with OpenAI to deploy at least 10 gigawatts of AI computing power. Under the plan, Nvidia will invest up to $100 billion as each gigawatt of NVIDIA systems is deployed nvidianews.nvidia.com. The first 1 GW is slated for late 2026 on Nvidia’s new “Vera Rubin” supercomputer. CEO Jensen Huang said this marks “the next leap forward — deploying 10 gigawatts to power the next era of intelligence” nvidianews.nvidia.com. OpenAI’s Sam Altman emphasized that “everything starts with compute,” and the new chips will fuel AI breakthroughs. This deal comes amid massive demand for AI chips – Nvidia will continue to serve all customers, but the investment ties OpenAI and Nvidia closely together nvidianews.nvidia.com nvidianews.nvidia.com.
28 September 2025
·········
1 … 16 17 18 19
Go toTop